We report three cases of multicentric Castleman's disease (MCD) 
Introduction

Castleman's disease is a lymphoproliferative disorder with benign hyperplastic lymph nodes; it is characterized histologically as hyaline vascular-type, plasma cell-type, or mixed-type (1). Patients with the plasma cell-or mixed-type Castleman's disease frequently experience systemic manifestations such as pyrexia, generalized fatigue, loss of appetite, weight loss, night sweats, splenomegaly, hepatomegaly, and skin rash (1). Abnormal laboratory findings include anemia, hypoalbuminemia, hypocholesterolemia, hypergammaglobulinemia, and increased levels of acute phase proteins (1). Localized Castleman's disease is termed unicentric Castleman's disease (UCD) and is curable by excision of the affected lymph nodes. However, multicentric Castleman's disease (MCD) is often refractory to treatment even with corticosteroids or chemotherapy. MCD is non-neoplastic, but the prognosis is poor without treatment.
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CRP level decreased to 0.31 mg/dl by January 25, 2006. On January 30, 2006, after 5 days of tocilizumab injection, pyrexia, lumbalgia, a constant urge to urinate and generalized fatigue occurred, and acute pyelonephritis was diagnosed by urinalysis. The white blood cell (WBC) count was
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